Efficacy of Liposomal Bupivacaine in Benign Soft Tissue Tumor Resection: A Randomized Controlled Trial

Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 4
SUMMARY

Liposomal bupivacaine (Exparel) has been used as an adjunct to pain management in the perioperative setting. However, the efficacy of the drug has not bewen studied in patients with benign soft tissue tumor resections. The goal of the study is to see if Exparel controls pain and improves functional outcomes for patients after these procedures compared to the current standard Bupivacaine HCL.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: Accepts Healthy Volunteers
View:

• All benign soft tissue tumors greater than one cubic cm

• Adults 18 years and older

Locations
United States
Oregon
Good Samaritan Regional Medical Center
Recruiting
Corvallis
Time Frame
Start Date: September 1, 2020
Estimated Completion Date: September 1, 2022
Participants
Target number of participants: 140
Treatments
Experimental: experimental
Exparel group
Active Comparator: control
plain bupivacaine
Sponsors
Leads: Samaritan Health Services

This content was sourced from clinicaltrials.gov

Similar Clinical Trials